Dillman R O, Koziol J A, Zavanelli M I, Beauregard J C, Halliburton B L, Glassy M C, Royston I
Cancer. 1984 Apr 1;53(7):1484-91. doi: 10.1002/1097-0142(19840401)53:7<1484::aid-cncr2820530710>3.0.co;2-t.
The authors performed a variety of lymphocyte-stimulation tests and quantified several lymphocyte subpopulations in 73 healthy controls and 72 patients with advanced cancer who were no longer receiving anticancer therapy. As a group, cancer patients had fewer lymphocytes and helper cells, but a greater proportion of suppressor cells and Ia+ cells than controls. The ratio of helper to suppressor cells was lower in the cancer group. Uptake of 125I-uridine was markedly depressed in cancer patients in the face of stimulation with various plant lectins, foreign lymphocytes, and varicella-zoster antigen. There was little correlation between any of the stimulation tests and any of the lymphocyte subpopulation proportions or numbers. The two tests that were most frequently abnormally low among the cancer patients were percent lymphocytes and number of helper cells (81% each). The most frequently abnormal functional assay in patients was pokeweed mitogen stimulation (59%). Three separate statistical methods selected the combination of percent lymphocytes, percent Ia+ cells, percent suppressor cells, number of helper cells, and pokeweed mitogen stimulation as being the best predictors of cancer/immunoincompetent status. This study confirms the breadth of immunoincompetence in advanced cancer patients as defined by in vitro techniques. A smaller battery of tests can be useful in monitoring the immune status of such patients, especially during therapy with proposed immune modulators.
作者对73名健康对照者和72名不再接受抗癌治疗的晚期癌症患者进行了多种淋巴细胞刺激试验，并对几种淋巴细胞亚群进行了定量分析。总体而言，癌症患者的淋巴细胞和辅助细胞数量较少，但与对照组相比，抑制细胞和Ia +细胞的比例更高。癌症组中辅助细胞与抑制细胞的比例较低。面对各种植物凝集素、异体淋巴细胞和水痘-带状疱疹抗原的刺激，癌症患者对125I-尿苷的摄取明显降低。任何刺激试验与任何淋巴细胞亚群比例或数量之间几乎没有相关性。在癌症患者中最常出现异常低值的两项检测是淋巴细胞百分比和辅助细胞数量（均为81%）。患者中最常出现异常的功能检测是商陆有丝分裂原刺激（59%）。三种独立的统计方法选择淋巴细胞百分比、Ia +细胞百分比、抑制细胞百分比、辅助细胞数量和商陆有丝分裂原刺激的组合作为癌症/免疫功能不全状态的最佳预测指标。这项研究证实了通过体外技术所定义的晚期癌症患者免疫功能不全的广度。一组较小的检测对于监测此类患者的免疫状态可能有用，尤其是在使用拟议的免疫调节剂进行治疗期间。
